Why Use Humanized Mouse Models for Translational Studies in Inflammatory Disorders?

On January 24th, TransCure BioServices and Mabylon AG joined our XTalks webinar “Why Use Humanized Mouse Models for Translational Studies in Inflammatory Disorders?“. This webinar showcased drug testing in humanized mice models in two therapeutic areas: Inflammatory Bowel Disease (IBD) and Food Allergies.

• Inflammatory Bowel Disease (IBD), which includes ulcerative colitis and Crohn’s disease, is characterized by chronic inflammation of the intestinal tract. Although conventional treatments such as immunomodulators can improve symptoms, a large number of patients do not respond to available treatments. In the first part of the webinar, Dr. Ho Wang Yin, PhD, CIO, will present how humanized mouse models can help develop new therapies for IBD. She will provide an overview of chemically induced models of acute colitis (DSS and TNBS), the advantages and disadvantages of each model, and a summary of typical study design.
• Peanut allergy affects up to 2% of the pediatric population and represents a high medical need, as peanut ingestion is the most common cause of food-induced anaphylaxis in the United States. Oral immunotherapy, the only FDA-approved therapy, is lengthy and carries the risk of severe side effects. In the second part of the webinar, Dr. Wuillemin will demonstrate the efficacy of MY006, a passive immunotherapy developed thanks to Mabylon’s unique antibody discovery platform for the treatment of peanut allergy in humanized mouse models.
  The webinar will be available online, from anywhere, as a recording, and free of charge.